华润双鹤：全资子公司盐酸替罗非班氯化钠注射液获得药品注册证书

Group 1 - The core point of the article is that China Resources Double Crane (华润双鹤) announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd. (安徽双鹤), has received a drug registration certificate for the injection of Rivaroxaban Sodium Chloride from the National Medical Products Administration [1] Group 2 - The drug registration certificate is a significant regulatory approval that allows the company to market and sell the Rivaroxaban Sodium Chloride injection in China [1] - This approval may enhance the company's product portfolio and potentially increase its market share in the pharmaceutical industry [1] - The development reflects the company's ongoing efforts to expand its offerings in the healthcare sector [1]